Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 19/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 0.60 |
| ▸ | CLK3 | P49761 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292339 | 1.00 | GSK3B (1.00) | GSK3BDYRK1ACLK2CLK3 | |
| SCHEMBL21311514 | 0.89 | DYRK1A (0.81) | GSK3BDYRK1ACLK2CLK3 | |
| SCHEMBL2088319 | 0.87 | DYRK1A (0.77) | GSK3BDYRK1A | |
| SCHEMBL2089776 | 0.86 | DYRK1A (0.76) | GSK3BDYRK1A | |
| SCHEMBL21311317 | 0.85 | DYRK1A (0.75) | GSK3BDYRK1ACLK2CLK3 | |
| SCHEMBL2086930 | 0.84 | DYRK1A (0.72) | GSK3BDYRK1A | |
| SCHEMBL2086929 | 0.84 | DYRK1A (0.72) | GSK3BDYRK1A | |
| SCHEMBL2086993 | 0.84 | DYRK1A (0.72) | GSK3BDYRK1A | |
| SCHEMBL2087371 | 0.84 | DYRK1A (0.72) | GSK3BDYRK1A | |
| SCHEMBL21292411 | 0.84 | DYRK1A (1.00) | GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2022-12-22 | — | — | US | disclosed |
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190263821-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-08-29 | — | — | US | disclosed |
| WO-2019165192-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | SAMUMED, LLC (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | GSK3B 11/4885DYRK1A 1/4885CLK2 89/4885 |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | GSK3B 11/4885DYRK1A 1/4885CLK2 89/4885 |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | GSK3B 11/4885DYRK1A 1/4885CLK2 89/4885 |
| US-20190263821-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | GSK3B 11/4885DYRK1A 1/4885CLK2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.